Literature DB >> 476441

Treatment of osteomalacia associated with primary biliary cirrhosis with oral 1-alpha-hydroxy vitamin D3.

J E Compston, J P Crowe, L W Horton.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 476441      PMCID: PMC1595727          DOI: 10.1136/bmj.2.6185.309

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  3 in total

1.  Synthesis of 1alpha-hydroxy [6-3H]vitamin D3 and its metabolism to 1alpha, 25-dihydroxy [6-3H]vitamin D3 in the rat.

Authors:  M F Holick; T E Tavela; S A Holick; H K Schnoes; F DeLuca; B M Gallagher
Journal:  J Biol Chem       Date:  1976-02-25       Impact factor: 5.157

2.  Treatment of osteomalacia associated with primary biliary cirrhosis with parenteral vitamin D2 or oral 25-hydroxyvitamin D3.

Authors:  J E Compston; L W Horton; R P Thompson
Journal:  Gut       Date:  1979-02       Impact factor: 23.059

3.  Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its 1alpha-hydroxylated derivatives.

Authors:  J A Kanis; R G Russell
Journal:  Br Med J       Date:  1977-01-08
  3 in total
  4 in total

1.  Guidelines on the management of osteoporosis associated with chronic liver disease.

Authors:  Jane D Collier; M Ninkovic; J E Compston
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

Review 2.  Hepatic osteodystrophy: vitamin D metabolism in patients with liver disease.

Authors:  J E Compston
Journal:  Gut       Date:  1986-09       Impact factor: 23.059

3.  Vitamin D deficiency, osteomalacia, and primary biliary cirrhosis. Response to orally administered vitamin D3.

Authors:  M Davies; E B Mawer; H J Klass; G A Lumb; J L Berry; T W Warnes
Journal:  Dig Dis Sci       Date:  1983-02       Impact factor: 3.199

Review 4.  Osteoporosis in primary biliary cholangitis.

Authors:  Christopher J Danford; Hirsh D Trivedi; Konstantinos Papamichael; Elliot B Tapper; Alan Bonder
Journal:  World J Gastroenterol       Date:  2018-08-21       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.